Pyxis Oncology, Inc. today announced positive preliminary data from its ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple solid tumors. PYX-201 achieved a confirmed 50% objective response rate (ORR) by RECIST 1.1, including one complete response, and a 100% disease control rate in six heavily pretreated head and neck squamous cell carcinoma (HNSCC) patients. Across all six solid tumor types of interest (n=31), PYX-201 demonstrated an overall 26% ORR with dose-dependent responses observed.
The company also announced a new Clinical Trial Collaboration Agreement with Merck to evaluate PYX-201 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). This combination study is expected to begin dosing patients in the first quarter of 2025 across indications including HNSCC, HR+/HER2- breast, TNBC, and sarcoma.
PYX-201 was generally well-tolerated with a favorable safety profile, showing a low incidence of dose discontinuation, interruptions, or delays due to treatment-related adverse events. Monotherapy expansion trials in HNSCC are also planned to begin dosing in the first quarter of 2025, with multiple data updates anticipated in 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.